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Abstract
Background and aim
The potential of microRNAs (miRNA) as non-invasive diagnostic, prognostic, and predictive
biomarkers, as well as therapeutic targets, has recently been recognized. Previous studies
have highlighted the importance of consistency in the methodology used, but to our knowl-
edge, no study has described the methodology of sample preparation and storage systemati-
cally with respect to miRNAs as blood biomarkers. The aim of this study was to investigate
the stability of miRNAs in blood under various relevant clinical and research conditions: differ-
ent collection tubes, storage at different temperatures, physical disturbance, as well as serial
freeze-thaw cycles.
Methods
Blood samples were collected from 12 healthy donors into different collection tubes contain-
ing anticoagulants, including EDTA, citrate and lithium-heparin, as well as into serum collec-
tion tubes. MiRNA stability was evaluated by measuring expression changes of miR-1, miR-
21 and miR-29b at different conditions: varying processing time of whole blood (up to 72
hours (h)), long-term storage (9 months at -80˚C), physical disturbance (1 and 8 h), as well
as in a series of freeze/thaw cycles (1 and 4 times).
Results
Different collection tubes revealed comparable concentrations of miR-1, miR-21 and miR-
29b. Tubes with lithium-heparin were found unsuitable for miRNA quantification. MiRNA lev-
els were stable for at least 24 h at room temperature in whole blood, while separated frac-
tions did show alterations within 24 h. There were significant changes in the miR-21 and
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miR-29b levels after 72 h incubation of whole blood at room temperature (p<0.01 for both).
Both miR-1 and miR-21 showed decreased levels after physical disturbance for 8 h in sepa-
rated plasma and miR-1 in serum whole blood, while after 1 h of disturbance no changes
were observed. Storage of samples at -80˚C extended the miRNA stability remarkably, how-
ever, miRNA levels in long-term stored (9 months) whole blood samples were significantly
changed, which is in contrast to the plasma samples, where miR-21 or miR-29b levels were
found to be stable. Repetitive (n = 4) freeze-thaw cycles resulted in a significant reduction of
miRNA concentration both in plasma and serum samples.
Conclusion
This study highlights the importance of proper and systematic sample collection and prepa-
ration when measuring circulating miRNAs, e.g., in context of clinical trials. We demon-
strated that the type of collection tubes, preparation, handling and storage of samples
should be standardized to avoid confounding variables influencing the results.
Introduction
The potential importance of circulating microRNA (miRNA) as non-invasive diagnostic,
prognostic, and predictive biomarkers, as well as therapeutic targets has been given great
attention [1–7]. MiRNAs are a class of small non-protein-coding RNA molecules that play
an essential role in gene regulation at the post-transcriptional level by causing messenger
RNA (mRNA) degradation or inhibiting mRNA translation into protein [8–13]. More than
2,500 miRNAs have been found in humans [14], and these appear to regulate 60% of the
human protein-coding genes [15]. With the discovery of miRNAs being expressed in clini-
cal samples such as plasma/serum [2,16–20], urine [21,22], and other bodyfluids [23,24]
miRNAs have evolved as potential biomarkers that may provide insights into the underlying
pathophysiological condition of a disease. Furthermore miRNAs have the potential of being
used for diagnostic purposes, and thereby guiding treatment strategies. However, when
used as clinical biomarkers, attention must be paid to the stability of miRNAs given the vari-
ous conditions the clinical samples are processed with respect to the specific methodology
and source of biological material (e.g., whole blood, plasma or serum) [25,26]. While RNA
molecules are known to be highly unstable, previous studies have indicated that miRNAs
are remarkably stable in plasma and serum, and resistant to RNase activity, as well as
extreme pH and multiple numbers of freeze-thaw cycles [2,16,17]. However, studies charac-
terizing and quantifying biomarkers in heart failure and atrial fibrillation patients were
lacking consistent and reproducible results concerning quantification of the miRNA con-
centration in blood samples of patients [27]. One possible explanation could be an incon-
sistency in the methodology used. Previous studies have highlighted that confounding
methodological factors should be ruled out [25,26,28]. To our knowledge, no study has
described the methodology of sample preparation and storage systematically with respect to
miRNAs as blood biomarkers. It is not known whether the time between blood collection
and processing of plasma/serum or physical disturbance of the samples affects the miRNA
levels and the reproducibility of results. Therefore, the aim of this study was to investigate
the stability of miRNA expression in whole blood and plasma/serum under various relevant
clinical and research conditions in several types of collection tubes.
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Materials and Methods
Study population and blood sample collection
This study was conducted in two different centers (Copenhagen, Denmark and Munich,
Germany). Blood samples were collected from 6 healthy donors (4 males and 2 females) in
Copenhagen, and 6 healthy donors (3 males and 3 females) in Munich. All were of Caucasian
ethnicity, except of 2 Asians in the Copenhagen cohort. For each study, whole blood was col-
lected by venous puncture with butterfly needles into 6 ml serum separator and/or anticoagu-
lant (salts of EDTA, lithium-heparin (at both study sites) and citrate (only at Copenhagen
site)) containing tubes at the same blood draw. All tubes were inverted 10 times for mixing
immediately after collection, and before further processing and storage. Participants provided
written informed consent before participation, and the study was conducted according to the
guidelines of The National Committee on Health Research Ethics, Denmark, and The Local
Ethics Committee of the University of Munich, Germany. All data used in this study were ana-
lyzed anonymously and according to the health research ethics committee system in Denmark
and the project did not need approval by the committees. Samples in Munich were collected in
a general biobanking effort that was approved by the local ethics committee.
Sample preparation and storage
To obtain plasma and serum, whole blood samples were either centrifuged at 3,000 revolution
per minute (rpm) at room temperature for 15 minutes (min) in Copenhagen or at 4,000 rpm
for 20 min at room temperature in Munich. The supernatant was immediately and carefully
removed with 1 cm from the buffy coat, and frozen in 1.8 ml RNase-free cryo-tubes, and stored
at -80˚C until further processing. Plasma was obtained as the cell-free supernatant remaining
after centrifuging blood, collected in the presence of an anticoagulant. Serum was collected as
the cell-free supernatant, accessible after centrifuging blood incubated at room temperature
for at least 30 min between collection and centrifugation to allow the blood in the serum sepa-
rator tubes to clot spontaneously.
RNA preparation
Total RNA was purified from a 300 μl sample, and the extraction was followed according to
the NucleoSpin1 (Macherey-Nagel, Germany) miRNA plasma protocol [29]. C. elegans miR-
39 (cel-miR-39) was spiked-in as a control for extraction efficiency, as previous described [16].
All samples were eluted in 60 μl of RNase/DNase free water and stored at -80˚C until further
analysis.
Reverse transcriptase reactions
Since the expression of miRNAs in the blood is very low, spectrophotometry is not reliable
for quantification. In order to compensate for potential variations we added cel-miR-39 as a
loading control (see above) and used a fixed volume of input RNA eluate as it was described
before [16]. Total cDNA was synthesized from total RNA (5 μl), following the manufacturer´s
instructions. TaqMan MicroRNA Reverse Transcription Kit (Life Technologies, USA) was
used for multiplex reverse transcription reactions carried out with the primer sets for hsa-
miR-1 (Life Technologies, USA), hsa-miR-21 (Life Technologies, USA), hsa-miR-29b (Life
Technologies, USA) and cel-miR-39 (Life Technologies, USA) (used as loading control for
extraction efficiency). The reactions were incubated in a Research Thermal Cycler (Applied
Biosystems, USA (at Copenhagen site) or Bio Rad iQ, Germany (at Munich site)) for 30 min at
16˚C, 30 min at 42˚C, 5 min at 85˚C and then held at 4˚C.
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Quantitative real-time polymerase chain reaction (qRT-PCR)
qRT-PCR was perfomed using TaqMan Gene Expression MasterMix (Life Technologies, USA)
and TaqMan probes (Life Technologies, USA) for hsa-miR-1 (Assay-ID: 000385), hsa-miR-21
(Assay-ID:000397), hsa-miR-29b (Assay-ID: 000413) and cel-miR-39 (Assay-ID: 000200)
according to manufacturer’s instructions under sterile conditions using either an Applied Bio-
systems 7300 Real-Time PCR System (Copenhagen samples) or a CFX 96 C1000 touch Realtime
Cycler (Bio Rad, Germany) (Munich samples). Reactions were run as triplicates using a total
reaction volume of 10 μl. Thermal cycling was performed as follows: 1. 95˚C for 10 minutes, 2.
95˚C for 15 seconds, 3. 60˚C for 60 seconds. Step 2 and 3 were repeated 44 times. The quantita-
tive endpoint of the qRT-PCR was the threshold cycle (CT), defined as the PCR cycle at which
the fluorescent signal of the PCR product crosses the detection threshold (set at 0.2 units).
Experimental procedures
Different blood tubes. Blood was directly collected into different blood tubes containing
serum separator and/or anticoagulant (salts of EDTA, lithium-heparin (at both study sites)
and citrate (only at Copenhagen site)). Blood was processed to plasma/serum and RNA was
isolated.
Impact of delayed processing. Whole blood samples were collected as described above
and were stored at room temperature up to 72 hours (h) and then used for RNA isolation.
Plasma and serum samples were processed immediately after blood collection and separated
fractions were incubated for 24 h or 4 days (d) before RNA was isolated.
Impact of disturbance. Blood samples were placed on a PMR 30 Mini Rocker Shaker
(Grant Instruments, UK). After 1 and 8 h of shaking at 30 rpm RNA was isolated.
Long-term storage. Samples of whole blood from the same blood draw, collected in
EDTA tubes, were either processed to plasma or left untouched, and the samples were stored
in parallel at -80˚C for either 1 day or 9 months prior to analysis.
Repetitive freeze-thaw cycles. Blood samples were processed immediately after blood col-
lection and aliquots of plasma and serum were stored at -80˚C. One aliquot was thawed once,
another aliquot was thawed and frozen four times before RNA was isolated.
Blood fractions. Samples of EDTA-treated whole blood from 3 subjects were separated
into three fractions: plasma, buffy coat, and red blood cells (RBC). The levels of miR-21 and
miR-29b were quantified in each of these fractions
Data analysis
The qRT-PCR data, miRNA quantification CT, were collected by SDS1.2 software (Applied
Biosystems, USA) and imported into Microsoft Excel, and the mean CT-values were calcu-
lated. Normalized ΔCT-values were calculated by subtracting the mean CT-value of cel-miR-39
from the mean CT value of the target miRNA for each sample.
Statistical analysis
Statistical analysis was performed using one-way analysis of variance (ANOVA), repeated
measures ANOVA, and where indicated post-hoc pairwise comparisons with Dunnett´s test,
and paired Student´s t-test. One-way ANOVA was applied to compare the miRNA levels
between blood tubes (Fig 1A and 1B) and storage at room temperature was assessed by the
repeated measures ANOVA test (Fig 2A and 2B). Impact of delayed processing and physical
disturbance (Fig 3A–3D), and blood fractions (Fig 4A–4D) were measured by one-way
ANOVA. Paired two-tailed t-test was applied to compare the miRNA levels between different
MicroRNAs – Pre-Analytic Methodological Considerations
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Fig 1. Different blood tubes for miRNA analysis. miRNA was isolated and levels of miR-1, miR-21 and miR-29b from either; EDTA-plasma, citrate-
plasma, lithium-heparin-plasma, or serum fraction, were detected by RT-qPCR. Values were normalized to a spike-in control, cel-miR-39. Normalized
averageΔCT values for each are shown, demonstrating amplification from all sources, except lithium-heparin-plasma. In the remaining samples, the
levels of miR-21 and miR-29b did not vary significantly between the blood tubes. Li = lithium, ND = not detectable. A) Copenhagen Cohort. B) Munich
Cohort.
doi:10.1371/journal.pone.0167969.g001
Fig 2. Stability of miRNA in whole blood incubated at room temperature. Whole blood was collected into EDTA containing tubes and incubated
for 0, 4, 8, 12, 24 and 72 h at room temperature before processed into plasma. qRT-PCR was performed. Statistically significant differences in miRNA
expression are marked with asterisks (**). **p<0.01. A) miR-21. B) miR-29b.
doi:10.1371/journal.pone.0167969.g002
MicroRNAs – Pre-Analytic Methodological Considerations
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samples (Figs 5, 6A, 6B and 7). A two sided P-value of<0.05 was considered statistically signif-
icant. Analyses were performed with SAS version 9.4 (SAS institute, USA) and GraphPad
PRISM 5.0 (GraphPad Software, USA).
Results
Different types of blood tubes for microRNA analysis
The following analysis describes the impact of the distinct blood preparation procedures with
respect to tube types used in this study. At both sites blood from 9 subjects was drawn into
Fig 3. Impact of delayed processing on separated blood fractions. Whole blood was collected into EDTA or serum separator containing tubes and
incubated at room temperature for 0h, 24h, and 4 days before processed into plasma (A) and serum (B) or processed into plasma (C) and serum (D)
immediately and then incubated at room temperature for 0h, 24h, and 4d. Data presented as normalized averageΔCTvalues±SEM. *p<0.05, **p<0.01,
***p<0.001.
doi:10.1371/journal.pone.0167969.g003
Fig 4. Impact of physical disturbance. Whole blood was collected into EDTA or serum separator containing tubes and incubated on a shaker at 30
rpm at room temperature for 0h, 1h, and 8h before processed into plasma (A) and serum (B) or processed into plasma (C) and serum (D) immediately
and then incubated on a shaker at 30 rpm at room temperature for 0 h, 1 h, and 8 h. Data presented as normalized averageΔCTvalues±SEM. *p<0.05,
**p<0.01, One-way ANOVA with Dunnet post test.
doi:10.1371/journal.pone.0167969.g004
MicroRNAs – Pre-Analytic Methodological Considerations
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different vacutainer tubes containing either serum separator or one of the following anticoagu-
lants: EDTA, lithium-heparin, or citrate (Copenhagen site only). MiR-1, miR-21 and miR-29b
could be detected in blood from all sources, except from lithium-heparin plasma (Fig 1). In the
remaining samples, the levels of miR-1, miR-21, and miR-29b did not vary significantly
between the blood tubes (p>0.05 for all).
Incubation of whole blood at room temperature for extended periods of
time
To mimic clinical blood sample handling, the stability of miRNAs incubated at room tempera-
ture for various duration was evaluated. In the Copenhagen cohort we measured miRNA levels
in EDTA-treated whole blood samples. At different experimental time points (0, 4, 8, 12, 24
and 72 h) whole blood was processed to plasma (Fig 2). These time points were chosen to
Fig 5. Incubation of plasma at -80˚C for up to 9 months. There was no significant change in miRNA
concentration up to 9 months after freezing for either miR-21 (A) or miR-29b (B) in plasma (p = 0.11 and
p = 0.96). However, the concentration of both miRNAs in whole blood increased during storage at -80˚C.
*p<0.05, **p<0.01.
doi:10.1371/journal.pone.0167969.g005
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represent typical short-term transport and storage conditions in the clinical laboratory. Signifi-
cant changes in the miRNA levels after 72 h were observed for miR-21 (p<0.01) and miR-29b
(p<0.01). However, miRNA concentrations were stable in whole blood at room temperature
for at least 24 h (p = 0.50 for miR-21 and p = 0.16 for miR-29b compared to T0).
Fig 6. MiRNA stability after repetitive freeze-thaw cycles within the separated fractions. Whole blood
was collected into EDTA or serum separator containing tubes, immediately processed into plasma (A) and
serum (B) and frozen at -80˚C. Samples were thawed one or four times before RNA was isolated and RT-
qPCR was performed. *p<0.05, **p<0.01, unpaired student t-test.
doi:10.1371/journal.pone.0167969.g006
Fig 7. MiRNA levels in the 3 blood fractions; plasma, buffy coat and red blood cells (RBC). The two
miRNAs, miR-21 and miR-29b, were differently distributed in the fractions; there are significant higher levels
of miR-21 in the buffy coat and RBC compared to plasma, and miR-29b plasma levels are significantly lower
than in the buffy coat. Statistically significant differences in miRNA expression are marked with asterisks (*).
**p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0167969.g007
MicroRNAs – Pre-Analytic Methodological Considerations
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In the Munich cohort we evaluated time-dependent effects on miR-1 and miR-21 levels in
already separated fractions of EDTA plasma and serum plasma samples in addition to whole
blood samples at room temperature after 24 h and 4 d (Fig 3). We could confirm the results
from the Copenhagen cohort demonstrating that miR-21 levels in EDTA-treated whole blood
are stable for at least 24 h (Fig 3A). In tubes containing serum separator miR-21 was stable
only for up to 24 h (Fig 3B) whereas miR-1 levels were stable up to 4 d. Separated plasma or
serum fractions showed significantly reduced miRNA levels after incubation for 24 h or 4 d
(Fig 3C and 3D).
MiRNA stability during physical and mechanical disturbance
To evaluate the effect of physical disturbances (e.g. transportation of blood samples from one
center to another center) different samples (EDTA whole blood, serum whole blood, EDTA
plasma fraction, serum fraction) were placed on a shaker for 1 or 8 h (Fig 4). The miRNA
expression of both miR-1 and miR-21 decreased significantly after 8 h of physical disturbance
in the separated plasma fraction (Fig 4C). In the serum fraction the results showed a more
stable profile revealing just a slight non-significant trend for a decreased concentration over
time (Fig 4D). Furthermore, we compared if the effect of physical disturbance differs in whole
blood vs. the separated fractions (plasma and serum). MiRNA expression in EDTA-treated
whole blood was stable after 1 or 8 h of disturbance (Fig 4A), in serum whole blood we ob-
served a significant reduction in miR-1 expression after 8 h whereas miR-21 expression
remained stable (Fig 4B). These results suggest no preventive effect of fraction separation prior
to mechanical stress.
Storage of plasma vs. whole blood at -80˚C
Next, we investigated whether long term storage at -80˚C had any effect on miRNA stability,
by examining the effect of storage conditions on miRNA expression. The analysis revealed that
storage of separated plasma at -80˚C for 9 months had no significant effect on miR-21 and
miR-29b levels (p = 0.11 and p = 0.96, respectively), while the concentration of free miRNAs
in whole blood increased during storage at -80˚C for both miRNAs over time (+3.47±0.83,
p<0.01 for miR-21 and +2.56±1.09, p = 0.04 for miR-29b) (Fig 5).
MiRNA stability after repetitive freeze-thaw cycles within the separated
fractions
In order to determine the reproducibility of results in laboratory routine and to evaluate the
stability of miRNAs in plasma and serum fractions with respect to repetitive freeze-thaw action
we performed another series of experiments. Using a sample that was stored at -80˚C and
thawed once as a reference a decrease in miRNA-concentrations after 4 cycles of freeze-thaw
was observed (Fig 6). These concentration changes were present for miR-21 (5.59±0.19 vs.
6.38±0.21, p<0.05) and miR-1 (15.57±0.69 vs. 16.31±0.62, p<0.05) in EDTA plasma samples
as well as for miR-21 (4.45±0.75 vs. 8.74±0.88, p<0.01) in serum samples.
MiRNA levels in fractionated blood
The levels of miR-21 and miR-29b were quantified in plasma, buffy coat, and RBC. We found
that the two miRNAs were differently distributed in the 3 fractions (Fig 7). We observed signif-
icantly higher levels of miR-21 in the buffy coat (+4.20±0.51, p<0.01) and RBC (+5.39±0.37,
p<0.001) compared to plasma, and miR-29b plasma levels are significantly lower than in the
buffy coat samples (+6.54±1.10, p<0.01).
MicroRNAs – Pre-Analytic Methodological Considerations
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Discussion
This study highlights several variables that could affect the concentration of miRNAs in whole
blood and in plasma/serum samples, respectively. To our knowledge, this study is the first to
provide detailed methodological information regarding the role of miRNAs as biomarkers,
which have to be taken into account for generating reliable and representative data for use in
clinical routine. We demonstrated that the type of collection tubes, preparation, handling and
storage of samples should be standardized to avoid confounding variables influencing the
results and to provide a solid basis for comparison of results between studies.
Blood collection and preparation
Collection of whole blood is the first step in the preparation of plasma and serum, and is
important for accurate analysis of miRNA expressions. The blood tubes containing serum sep-
arator or the anticoagulants, EDTA and citrate, do not significantly change the detectible levels
of miRNAs. In contrast, the presence of lithium-heparin makes detection of the three miRNAs
impossible. Both plasma and serum samples have been used for circulating miRNA analysis
[20], and although all tubes used in our study were effective (except lithium-heparin), there
were subtle differences for miRNA-expression in EDTA plasma vs. citrate plasma vs. serum
fraction samples. Previous studies have shown that different centrifugation protocols can pro-
duce platelet-rich or platelet-poor plasma, which could lead to different amounts of blood cell
contamination in these fluids [30], and the coagulation process may also affect the concentra-
tion of miRNAs [26]. Furthermore, the samples of the Munich cohort showed a larger variabil-
ity of serum results in comparison to plasma EDTA (data not shown). This data indicates that
samples collected from different blood tubes and blood fractions should not be included in the
same study or directly compared to each other, in order to avoid confounding of the results.
Stability of miRNA in whole blood before processing to plasma
Previous studies have shown that plasma miRNAs are stable under various conditions [16,20].
We found a significant change in the miR-21 and miR-29b levels after 72 h of incubation of
whole blood at room temperature, yet no changes were observed after 24 h at room tempera-
ture. These findings indicate that miRNAs may be released from blood cells and platelets, and
argues for storing only processed samples (plasma or serum) rather than whole blood. Our
study is in line with previous studies reporting only small variations in plasma miRNA levels at
room temperature up to 24 h [2,20], and indicates that the storage of whole blood at room
temperature under clinical conditions for extended periods of time (at least up to 24 h) prior
to the separation of plasma does not appear to affect plasma miRNA concentrations. Neverthe-
less, separated fractions of plasma seem to be less stable showing significant changes already
within 24 h after blood collection and separation. In view of these results it is important to
keep in mind that samples should still be processed as fast as possible or in a systemic temporal
fashion. In case of a longer blood processing periods whole blood samples should be preferred.
Still, the possibility that the stability of distinct miRNAs may be different should be taken into
account; the result of this study only reflects the stability of miR-1, miR-21, and miR-29b.
MiRNA stability during physical disturbance
Physical disturbance resulted in decreased levels of miRNAs in whole blood and separated
fractions of plasma and serum. The difference was only significant for serum whole blood and
separated plasma after 8 h of disturbance, but a trend towards a decrease over time was detect-
able for all the measurements. However, whole blood samples seem to be more robust than the
MicroRNAs – Pre-Analytic Methodological Considerations
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separated fractions in conditions of physical stress, but they still show a similar trend of
decreasing miRNA levels over time. So far, no report on miRNA stability in whole blood,
plasma or serum during transport or physical disturbance has been published. The reason for
the reduced miRNA expression after disturbance remains highly speculative. It is not very
likely that contaminating cells (e.g. platelets) are the reason since lysis of cells would result in
increased miRNA expression. A potential explanation is plasma inhibitors that might be acti-
vated by mechanical disturbance, i.e. shaking might provide sufficient activation energy for
inhibitors to become active. Nevertheless, translating our results into a clinical practice long-
term physical disturbance of blood samples, e.g., in context of transportation, should be
avoided to prevent artificial altered results of miRNA concentration.
Storage at -80˚C
In our study long-time storage at -80˚C had no significant effect on miRNA expression up to 9
months after freezing for either miR-21 or miR-29b in EDTA plasma samples. In contrast,
increased levels of free miRNA in whole blood samples were found 9 months after freezing.
These findings indicate that miRNAs may be released from blood cells and platelets, and
argues for storing only processed samples (plasma or serum) rather than whole blood. Addi-
tionally, a previous study has shown that hemolysis during sample preparation can change the
level of miRNAs, producing artificially high miRNA concentrations [31].
Repetitive freeze-thaw cycles
MiRNA levels (miR-1 and miR-21) were decreased after four repetitive freeze-thaw cycles in
plasma and serum. A similar effect has been shown previously by Zhao et al. [32]. They evalu-
ated miR-346 and miR-134 and could demonstrate reduced miRNA levels in samples that
were frozen/thawed. The effect observed in our study was not as striking but may be mimic a
biological signal. Interestingly, Farina et al. observed the opposite effect [33]. In their study
the serum expression of several miRNAs, including miR-21, was increased after two freeze-
thaw cycles. These results suggest that multiple measurements of a frozen sample should be
done with caution for direct comparison of results. Assuming a systematic effect, the relative
changes between groups should be less pronounced, but are not predictable.
MiRNA levels in the three separated blood fractions
Human blood consists of RBC (erythrocytes), platelets, and white blood cells (leukocytes,
buffy coat) suspended in plasma. We found that both miR-21 and miR-29b are present in all 3
blood fractions and that they are differentially distributed in the fractions. This underscores
the danger of contamination of the plasma by cells from the cellular pellet during aspiration or
hemolysis.
Limitations
In the current study we focused on miR-1, miR-21 and miR-29b, however, we do acknowledge
that the stability of these miRNAs may not be representative of all miRNAs in plasma, includ-
ing miRNAs with either higher or lower expression level. Whether these results can be extrap-
olated to other miRNAs requires additional studies. Furthermore, we only studied a small
number of individuals, which bears the potential of false-negative results due to insufficient
statistical power. However, even within this small number of individuals we were able to iden-
tify potential variables affecting results which should be considered before initiating a clinical
study. The majority of the study persons were Caucasians. Therefore, our results cannot be
MicroRNAs – Pre-Analytic Methodological Considerations
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generalized to other non-Caucasian individuals. It could be speculated that the stability of the
miRNAs may be confounding due to slightly different processing protocols in the two centres.
However, this highlights even more the importance of standardized methodology. Another
limitation of our study is the lack of a reliable housekeeping miRNA for normalization.
Although some miRNAs are supposed to be stably expressed in human blood (e.g. miR-16),
we could see significant variation of these miRNAs when measuring a large set of patient sam-
ples from our institution’s biobank (unpublished data). Therefore, we used cel-miR-39 as a
spiked-in control as described above.
Conclusion
This study aimed to investigate how variation in preparing and handling samples could influ-
ence the analysis of circulating miRNA in clinical practice. We found that miR-1, miR-21 and
miR-29b levels are stable for at least 24 h at room temperature in whole blood. Storage of sam-
ples at -80˚C extended the miRNA stability remarkably, however, miRNA levels in long-term
stored (9 months) whole blood samples were significantly changed, which is in contrast to the
plasma samples, where miRNA levels were found to be stable. Furthermore, we found that dis-
turbance of the plasma/serum sample as well as repetitive freeze-thaw cycles result in reduced
miRNA levels. This study highlights the importance of proper and standardized sample collec-
tion and preparation. Our data suggest that standardized procedures are required to overcome
challenges with miRNA stability, thus enabling the use of miRNAs as non-invasive diagnostic,
prognostic, and predictive biomarkers that provide valid results and the option of comparability.
Future Implications
Based on our current study we suggest following a standardized protocol for blood collection,
sample handling, processing and storage in order to obtain reproducible miRNA expression data:
1. Lithium heparin collection tubes should be avoided; for plasma collection we suggest to use
either EDTA or citrate containing tubes;
2. Sample processing should be performed carefully. Contamination of plasma/serum samples
with cellular fractions should be avoided;
3. Whole blood samples should not be stored at -80˚C, but should be separated into plasma/
serum fraction that can be stored at -80˚C without quality loss for at least 9 months;
4. We recommend to process blood samples immediately into blood fractions and store them
at -80˚C. If immediate processing/freezing is not possible, whole blood samples can be kept
at room temperature for up to 24 h. Separated plasma/serum samples, however, should be
frozen within 24 h of separation;
5. Physical disturbance can affect the stability of miRNAs. We therefore recommend to mini-
mize shaking of samples as far as possible. If transfer to another center is necessary, whole
blood samples seem to be more stable than separated plasma/serum samples;
6. We recommend to aliquot plasma/serum samples before storage at -80˚C since repetitive
freezing-thawing affects miRNA stability.
Supporting Information
S1 Table. Different blood tubes for miRNA analysis. MicroRNA was isolated and levels of
miR-1, miR-21 and miR-29b from either; EDTA-plasma, citrate-plasma, lithium-heparin-plasma,
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or serum fraction, were detected by RT-qPCR. Values were normalized to a spike-in control, cel-
miR-39. Absolute CT values for each are shown, demonstrating amplification from all sources,
except lithium-heparin-plasma. Note: measurements for miR-21 and miR-1 in the Munich cohort
were performed on the same participants but blood was collected at different days which made an
additional cel-miR-39 measurement necessary. Measurement of miR-1 in serum failed in 2 partic-
ipants. Li-Hep = lithium-heparin, CIT = citrate, n.a. = not available, - = not performed.
(DOCX)
S2 Table. Stability of miRNA in whole blood incubated at room temperature. Whole blood
was collected into EDTA containing tubes and incubated for 0, 4, 8, 12, 24 and 72 hours at
room temperature before processed into plasma. qRT-PCR was performed. Absolute CT values
for each miRNAs are shown.
(DOCX)
S3 Table. Impact of delayed processing (miR-21). Samples were processed immediately after
blood collection and separated fractions were incubated for 24 h or 4 days (d) before RNA was
isolated. Note: measurements for miR-21 and miR-1 in the Munich cohort were performed on
the same participants but blood was collected at different days which made an additional cel-
miR-39 measurement necessary. Measurements in EDTA whole blood, serum and serum
whole blood failed in 2 participants.
(DOCX)
S4 Table. Impact of delayed processing (miR-1). Samples were processed immediately after
blood collection and separated fractions were incubated for 24 h or 4 days (d) before RNA was
isolated. Note: measurements for miR-21 and miR-1 in the Munich cohort were performed on
the same participants but blood was collected at different days which made an additional cel-
miR-39 measurement necessary. Measurements in EDTA whole blood, serum and serum
whole blood failed in 2 participants.
(DOCX)
S5 Table. Impact of disturbance (miR-21). Blood samples were placed on a PMR 30 Mini
Rocker Shaker (Grant Instruments, UK). After 1 and 8 h of shaking at 30 rpm RNA was iso-
lated. Note: measurements for miR-21 and miR-1 in the Munich cohort were performed on
the same participants but blood was collected at different days which made an additional cel-
miR-39 measurement necessary. Measurements in EDTA whole blood (miR-21 and miR-1),
serum and serum whole blood (only miR-1) failed in 2 participants.
(DOCX)
S6 Table. Impact of disturbance (miR-1). Blood samples were placed on a PMR 30 Mini
Rocker Shaker (Grant Instruments, UK). After 1 and 8 h of shaking at 30 rpm RNA was iso-
lated. Note: measurements for miR-21 and miR-1 in the Munich cohort were performed on
the same participants but blood was collected at different days which made an additional cel-
miR-39 measurement necessary. Measurements in EDTA whole blood (miR-21 and miR-1),
serum and serum whole blood (only miR-1) failed in 2 participants.
(DOCX)
S7 Table. Incubation of plasma at -80˚C for up to 9 months. Absolute CT values for each
microRNAs are shown.
(DOCX)
S8 Table. Impact of repetitive freeze-thaw cycles. Blood samples were processed immediately
after blood collection and aliquots of plasma and serum were stored at -80˚C. One aliquot was
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thawed once, another aliquot was thawed and frozen four times before RNA was isolated.
Note: measurements for miR-21 and miR-1 in the Munich cohort were performed on the
same participants but blood was collected at different days which made an additional cel-miR-
39 measurement necessary. Measurement of miR-1 in serum failed in 2 participants.
(DOCX)
S9 Table. MiRNA levels in the 3 blood fractions; plasma, buffy coat and red blood cells
(RBC). Absolute CT values for each microRNA are shown.
(DOCX)
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